Alexion acquires Enobia Pharma Alexion Pharmaceuticals.
Alexion acquires Enobia Pharma Alexion Pharmaceuticals, Inc. today announced that the business has completed its previously announced acquisition of 100 percent of the capital stock of Enobia Pharma Corp., an exclusive biopharmaceutical company centered on the advancement of therapies to take care of patients with ultra-rare and life-threatening genetic metabolic disorders synthroid . Goldman, Sachs & Co. Acted as economic advisor to Alexion. Ropes and Gray LLP acted as lead lawyer to Alexion and Cassels Brock & Blackwell LLP acted as Canadian lawyer to Alexion.
The prospective major endpoint was the switch in platelet count from baseline, a way of measuring TMA, at 26 weeks. Key potential secondary endpoints included TMA event-free status , improvements in chronic kidney disease stage, and change in standard of living. Improvement in Platelet Count: A Measure of TMA Reduction The primary endpoint of the study, switch in platelet count, more than doubled through 26 weeks of treatment compared to baseline , a standard measure of kidney function, improved sufficiently to bring about an improvement of at least one stage in CKD in 65 percent of individuals , and eGFR increased significantly less than one CKD stage in four extra patients.